Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Management of community-acquired pneumonia in the emergency department

Jerome A. Leis and Wayne L. Gold
CMAJ March 20, 2012 184 (5) 559; DOI: https://doi.org/10.1503/cmaj.111143
Jerome A. Leis
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne L. Gold
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

See also practice article by Mumoli and Cei on page 560 and at www.cmaj.ca/lookup/doi/10.1503/cmaj.111256

Community-acquired pneumonia is life-threatening and timely administration of antibiotics is a goal of therapy

In-hospital mortality associated with community-acquired pneumonia is comparable to that with acute myocardial infarction.1 Patients with suspected community-acquired pneumonia require urgent assessment and therapy; however, overemphasis on time to first dose of antibiotics may lead to unnecessary administration of antibiotics for noninfectious diseases.2 Because of a lack of convincing evidence, guidelines no longer specify a four-hour window for starting antibiotics for patients who require admission to hospital but instead recommend that the first dose be given in the emergency department.2,3

Pretreatment diagnostic tests should be requested on a case-by-case basis

Routine cultures of blood and sputum are controversial because of their low yield and impact on treatment decisions. These tests are optional for outpatients; however, they should be ordered for patients who require admission to hospital, even in the absence of fever, if there is an increased risk of unusual or resistant pathogens that would require a change of empiric therapy or duration. This includes patients with severe community-acquired pneumonia, an immunocompromised state, alcohol abuse, structural lung disease, the presence of a pleural effusion and those who have recently travelled, as well as those for whom outpatient therapy has failed.3

Severe disease requires early recognition and prompt referral to intensive care

Current guidelines recommend early referral to intensive care for patients with hypotension despite aggressive fluid resuscitation, hypothermia, elevated respiratory rate (> 30 breaths/min), PaO2/FiO2 ratio < 250, leukopenia [< 4 × 109/L], multilobar consolidation, thrombocytopenia (< 100 × 109/L), confusion or uremia (blood urea nitrogen ≥ 20 mmol/L).3 The presence of three or more of these criteria has recently been validated in a prospective observational trial for predicting need for intensive care.4

Determining who can receive treatment as an outpatient should be guided by validated scoring systems

Predictive scores including the CURB-65 (Confusion, Uremia, Respiratory rate, low Blood pressure, age ≥ 65 years) or Pneumonia Severity Index are useful for identifying those at low risk of death who may be safely cared for as outpatients.3 A patient’s oxygen saturation (Sp02) on room air is increasingly recognized as a stand-alone criterion for discharge decisions. A recent prospective cohort study of 2923 patients with community-acquired pneumonia showed that those discharged from the emergency department with an Sp02 of less than 90% had increased combined 30-day mortality and admission rates (odds ratio 1.7; 95% confidence interval 1.1–2.8; p = 0.032).5 When an Sp02 of 92% or greater was used, the association with adverse events was no longer present.

Outpatient therapy should take into account risk factors for drug-resistant Streptococcus pneumoniae

Patients with exposure to macrolides, trimethoprim–sulfamethoxazole or respiratory fluoroquinolones in the past three months are at least four times more likely than those without such exposure to be infected with a pneumococcal isolate that is resistant to the same class of antibiotics.6 Although macrolides are the recommended first-line agents for those treated as outpatients, patients with recent macrolide exposure or who live in regions with high rates of macrolide resistance (> 25%) should receive alternate forms of empiric therapy.3,6 Treatment options include the addition of amoxicillin or amoxicillin–clavulanate or monotherapy with a respiratory fluoroquinolone.3

Footnotes

  • This article has been peer reviewed.

  • For references, please see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.111143/-/DC1

  • Competing interests: None declared.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (5)
CMAJ
Vol. 184, Issue 5
20 Mar 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Management of community-acquired pneumonia in the emergency department
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Management of community-acquired pneumonia in the emergency department
Jerome A. Leis, Wayne L. Gold
CMAJ Mar 2012, 184 (5) 559; DOI: 10.1503/cmaj.111143

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Management of community-acquired pneumonia in the emergency department
Jerome A. Leis, Wayne L. Gold
CMAJ Mar 2012, 184 (5) 559; DOI: 10.1503/cmaj.111143
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Community-acquired pneumonia is life-threatening and timely administration of antibiotics is a goal of therapy
    • Pretreatment diagnostic tests should be requested on a case-by-case basis
    • Severe disease requires early recognition and prompt referral to intensive care
    • Determining who can receive treatment as an outpatient should be guided by validated scoring systems
    • Outpatient therapy should take into account risk factors for drug-resistant Streptococcus pneumoniae
    • Footnotes
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Community-acquired pneumonia
  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Infection control in the emergency department
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Respiratory medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire